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Abstract: Asthma affects more than 300 million people worldwide and its prevalence is still rising. Acute asthma attacks 
are characterized by severe symptoms such as breathlessness, wheezing, tightness of the chest, and coughing, which may 
lead to hospitalization or death. Besides the acute symptoms, asthma is characterized by persistent airway inflammation 
and airway wall remodeling. The term airway wall remodeling summarizes the structural changes in the airway wall: 
epithelial cell shedding, goblet cell hyperplasia, hyperplasia and hypertrophy of the airway smooth muscle (ASM) 
bundles, basement membrane thickening and increased vascular density. Airway wall remodeling starts early in the 
pathogenesis of asthma and today it is suggested that remodeling is a prerequisite for other asthma pathologies. The 
beneficial effect of bronchial thermoplasty in reducing asthma symptoms, together with the increased potential of ASM 
cells of asthmatics to produce inflammatory and angiogenic factors, indicate that the ASM cell is a major effector cell in 
the pathology of asthma. In the present review we discuss the ASM cell and its role in airway wall remodeling and 
angiogenesis. 
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AIRWAY WALL REMODELING 
 One of the distinct features of the asthmatic lung is 
airway wall remodeling, which refers to persistent cellular 
and structural changes in the airway wall. In progressive 
disease, airway remodeling includes epithelial goblet cell 
hypertrophy, enhanced collagen deposition and airway wall 
hyperplasia. As early as 1922, it was recognized that the 
lungs of asthmatic patients are characterized by an increased 
thickness of the airway wall, in particular by an enlarged 
bulk of smooth muscle mass [1]. We now know that this 
increase is predominantly caused by mesenchymal (or: 
airway tissue forming) cells and a correlation between 
airway wall thickness and disease severity has been 
established [2-4]. In the asthmatic airway wall, we usually 
observe basement membrane thickening, hyperplasia and 
hypertrophy of ASM cells, and increased vascularity. In 
addition, we often observe epithelial cell shedding and 
thickening, goblet cell hyperplasia, and mucus gland 
hypertrophy [5-8]. It remains a matter of debate whether the 
immune system is the key player in asthma pathogenesis or 
whether tissue-forming lung cells are sufficient to explain 
the development of asthma [9]. The latter view is supported, 
however, by the observation that airway wall remodeling is 
observed in preschool children without clinical signs of 
inflammation [10-17]. Thickening of the airway wall sub-
epithelial cell layers, together with the edematous effects of 
increased numbers of blood vessels results is airway  
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narrowing, the major long term complication of asthma [18]. 
Fig. (1A-D) illustrates several of the pathologies of the 
remodeled airway wall as it can be observed in asthma 
patients. 
CELLS OF THE AIRWAY WALL 
 Traveling from the airway lumen down towards the 
connective tissue in the deeper regions of the airway wall, 
we first encounter the epithelium (Fig. 2). Epithelial cells 
have long been considered merely a mechanical barrier 
protecting the body from the environment. It is the first 
barrier against all influences from outside (allergens, 
pollutants, temperature, etc.) and has been reported to be 
damaged and metaplastic (pseudostratisfied) in asthma. 
Epithelial cells produce a vast spectrum of cytokines and 
chemokines [19, 20]. It has been shown that epithelial cell 
proliferation in asthmatics is impaired, which was attributed 
to altered level of several markers of proliferation such as 
proliferating cell nuclear antigen (PCNA), Ki67, and p21 
[21-23]. Furthermore, in asthmatics the composition of the 
extracellular matrix, which forms hemi-desmosomes with 
the epithelial cells, is altered and the expression of tight-
junction proteins is reduced [24-26]. These findings suggest 
a chronic injury of the airway epithelium with reduced 
ability to repair and may underlay the increased sensitivity to 
aspecific (e.g. cold air) and specific stimuli (e.g. smoke, 
ozone), as well as the increased release of pro-inflammatory 
factors [23, 27, 28]. 
 Directly beneath the epithelium we encounter the 
basement membrane (BM), a thin but robust sheet of fiber-
structured proteins (e.g. collagens, fibronectins). In healthy 
lungs, the thickness of the BM measures 5–7 µm, while in 
asthmatics the size can be found increased up to 5 times [29, 
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; compare Fig. 1C, 1D]. A multitude of cell types present in 
the lung can potentially contribute to BM thickening through 
a distorted deposition of extracellular matrix (ECM) 
components. Thickening of the asthmatic BM is due to 
increased deposition of collagen I and III, tenascin, and 
fibronectin, likely produced by activated myofibroblasts [30, 
31]. Several studies demonstrated that the BM is thickened, 
even in young asthmatic children and this thickening is 
comparable to that observed in adults [15, 24, 32, 33]. The 
increased BM thickening has been shown to be correlated 
with ASM cell mass, indicating that alterations in ECM 
composition and subsequent BM thickening may be 
dependent depend on the activity of ASM cells [34]. 
Furthermore, the ECM is a reservoir for secreted factors, 
which can be released upon degradation/reconstruction of the 
ECM within the tissue. VEGF for instance binds to the ECM 
through heparan sulphate proteoglycans and is released upon 
matrix degradation processes [35, 36]. When airway 
remodeling was reported for the first time it was described as 
a thickening of the BM [1]. Decades after this first 
description of BM thickening electron-microscopy revealed 
that the thickened layer is not the BM itself but a zone 
adjacent to it – the lamina reticularis [37]. Among chronic 
inflammatory lung diseases, which are also accompanied by 
ECM alterations (e. g. cystic fibrosis or chronic obstructive 
pulmonary disease (COPD)) BM thickening – including 
alterations in dimension and composition – is a unique 
pathology of asthma [38]. The thickening of the BM has also 
impact on the efficacy of treatment, as it was correlated with 
a limited short-term responsiveness to GC treatment [39]. 
 
Fig. (1). Top: Milligan’s trichrome stained sections of airway tissue from non-asthma (A) and asthma (B) patients. Images are representative 
of tissues obtained from 3 non-asthmatic and 3 asthmatic patients. Nuclei and muscle: magenta, collagen: green, RBC: orange. Note 
epithelial hyperplasia, thickening of muscle bundles and basement membrane, and increased microvessel density in asthmatic airways. E = 
epithelium, MB = muscle bundles, BM = basement membrane, MV = microvessels. Bottom: Light microscopic images of Haematoxylin-
Eosin-stained airway tissue sections obtained from a non-asthma (C) and an asthma (D) patient. Note the increased thickening of the 
basement membrane in the asthmatic airways. E = epithelium, arrows are indicating the basement membrane. (Figure adapted from 
references 89 and 106). 
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 Traveling further down the airway wall, we now enter the 
submucosa. This layer predominatly exists of connective 
tissue (CT) and mesenchymal cells, in particular fibroblasts 
(Fig. 2). Normally, the submucosa is scarsely vascularized 
and only few micro vessels are observed. In contrast, the 
submucosa of asthmatic patients is characterized by a 
marked intensification of vascularity, as well as an increased 
presence of eosinophils and mast cells (compare Fig. 1A, B). 
In the asthmatic lung, eosinophils have long been recognized 
as important immunomodulatory cells involved in airway 
wall remodeling. Indeed, depletion of eosinophil-derived 
cytokines reduced deposition of ECM proteins in the 
subepithelial BM of mild atopic asthmatics [40, 41]. 
Furthermore, eosinophils produce TGF-β1 which promotes 
proliferation of fibroblasts, as well as myo-fibroblast 
maturation and collagen synthesis [42]. Eosinophils and mast 
cells produce several angiogenic factors, including VEGF, 
and may thus help to direct angiogenesis in the asthmatic 
submucosa [43-46]. 
 Travelling still further down the airway wall, we finally 
touch the most striking feature of the asthmatic airway wall: 
the distinctive increase of the bulk of ASM cells [47, 48; 
compare Fig. 1A, B]. Smooth muscle cells, which surround 
the airways from the trachea down to the alveolar ducts, are 
the effector cells that determine the diameter of the airways. 
These are the cells that make the airways to relax or to 
constrict. Bronchoconstriction is the most severe symptom of 
an asthma attack and ASM cells are the major effector cells 
and the proximal cause of the excessive airway narrowing 
[49]. The constriction is completely or partially reversible, 
but sometimes only with the help of bronchodilating drugs. 
Two features of ASM cells are characteristic for asthma 
patients. First, we observe airway hypersensitivity, which 
refers to the increased response of ASM cells to low doses of 
stimuli. Second, the ASM cell of asthmatics demonstrates 
hyperreactivity, which describes an abnormal strong 
bronchoconstrictive response. Together, hypersensitivity and 
hyperreactivity of the ASM cell add up to the well-known 
asthma-characteristic airway hyperresponsiveness (AHR) 
[50], AHR can be induced by a plethora of environmental 
and/or systemic alterations, including allergen-challenge, 
sudden temperature changes, reduced humidity, exercise, 
increased inflammatory mediators, viral infections, etc. The 
bio-molecular cause for AHR remains unclear, however, 
although it may be due to fundamental changes within the 
ASM cell [51-53]. It should be noted, however, that the 
asthmatic ASM cell itself is not contracting stronger. Rather, 
the increased number of ASM cells (hyperplastia) causes a 
faster contraction relative to healthy individuals, in addition 
to an impaired relaxation [54, 55]. The increased ASM mass 
is already present in young adults (17-23y) [56] and in 
children without any signs of eosinophilic inflammation [12, 
57]. This suggests that the increased number of ASM cells 
may be the cause rather then the consequence of progressing 
disease. In addition, ASM cells are highly productive cells, 
in the sense that they produce a variety of inflammatory and 
angiogenic mediators, including GM-CSF, IL-1β, IL-2, IL-5, 
IL-6, IL-8, IL-11, IL10, Eotaxin, bFGF, PDGF-BB and 
VEGF [58]. In addition, ASM cells of asthmatic patients 
have a distinct hyper-reactive (“primed”) phenotype, which 
is characterized by an increased release of pro-inflammatory 
factors and mediators. For instance, ASM cells of asthmatics 
release more IL-6 and IL-8 after stimulation with house dust 
mite (HDM) extracts or after rhinovirus infection [51, 52]. 
The release of many of the aforementioned cytokines can be 
induced by several stimuli or in paracrine and autocrine 
regulated mechanisms. This shows that ASM cells of the 
airways provide a mechanism how inflammation may be 
 
Fig. (2). From the airway lumen down towards the connective tissue (CT) in the deeper regions of the airway wall we successively encounter 
the epithelium, the basement membrane, the submucosa (SM) containing mesenchymal cells (predominantly fibroblasts) and microvessels, 
and finally smooth muscle cells. 
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amplified and/or perpetuated without the involvement of 
immune cells. Furthermore, ASM cells are an important 
source of ECM components. ASM cells incubated with 
serum obtained from asthma patients demonstrated an 
increased production of fibronectin, lamin-γ, and 
proteoglycans [53, 59, 60]. In addition, ASM cells from 
asthmatics produce more connective tissue growth factor 
(CTGF), which may further contribute to BM thickening (as 
described above) [61, 62]. It is also of note that the number 
of mast cells in deeper regions of the airway wall is 
markedly increased and it has been suggested that mast cells 
are involved in “programming” (or “priming”) the adjacent 
ASM cells of asthmatics [63-67]. In contrast to the mast cells 
present in the submucosa, the mast cells located in the ASM 
bundles are always tryptase and chymase positive (MCTC) 
and their number has been linked to the severity of asthma 
[68] and airway hyperresponsiveness [63]. Mast cells are 
thought to be a major source of angiogenic factors in the 
lung and the number of tryptase-positive mast cells has been 
correlated with angiogenesis in human endometrial cancer 
[69]. 
ANGIOGENESIS 
 Angiogenesis refers to the formation of new blood 
vessels from endothelial cells, a complex process involving 
multiple factors with either promoting (angiogenic) or 
counteracting (angiostatic) actions. 
 In diseases associated with a pathological increase in 
vasculature, such as the submucosa of asthma patients, the 
net balance must be shifted towards pro-angiogenic factors. 
This can be accomplished through a reduction of angiostatic 
factors, the increase of angiogenic factors or a combination 
of both. The first report that vascular abnormalities occur in 
the airways of asthma patients was published in 1960, when 
Dunhill and coworkers reported the dilatation of blood 
vessels in lung tissue from asthma patients [70]. Currently, it 
is well-documented that the sub-epithelial submucosa of the 
lungs of asthmatic patients displays an increased vascular 
density – both ex vivo and in vivo [24, 71-73]. In addition, 
several abnormal modifications of the bronchial vasculature 
have been described in the asthmatic airways. In asthmatic 
humans, as well as in animal models of asthma, the blood 
flow in the lung is increased [74-77]. Morover, the vessels 
present in the submucosa of asthmatics are more permeable 
[78]. This not only leads to edema, it is also a prerequisite 
for tissue inflammation, as the extravasation of inflammatory 
cells to the tissue requires transmigration through the 
endothelium. 
 Increased vascularization has been shown to correlate to 
airflow limitation [71, 79, 80] and bronchial 
hyperresponsiveness [80-82], hence contributing 
significantly to the pathology of asthma. Additional studies 
provided further evidence that vascular density and asthma 
severity are linked [46, 83-85]. Furthermore, in the 
submucosa of asthma patients increased levels of VEGF, 
bFGF and angiogenin have been observed [86-88]. Simcock 
and coworkers demonstrated that human ASM cells of 
asthmatic patients produced higher levels of angiogenin, 
angiopoietin, VEGF, EGF, IGF-1, IFNγ, TIMP-1 and TIMP-
2 in response to stimulation with either IL-13 or TGF-β [86, 
87]. Recent studies in our laboratory demonstrated that 
human ASM cells of asthma patients also released 
significanly more VEGF, angiogenin, IL-6, MCP-1 and 
importantly three CXCR2 ligands, namely ENA-78, GRO-α 
and IL-8 [89]. 
 CXC-chemokines and their receptors are responsible for 
the progression of many solid tumors, including breast 
cancer, bronchogenic carcinomas, and malignancies of the 
gastrointestinal tract, prostate cancer, ovarian cancer, 
glioblastoma, as well as head and neck cancer [90-95]. CXC-
chemokines are also involved in several lung diseases, which 
involve altered angiogenesis such as idiopathic pulmonary 
fibrosis, obliterative bronchiolitis, or acute respiratory 
distress syndrome [96-98]. Comparing the angiogenic 
potential of ASM cells of asthmatic patients to those of non-
asthmatics, we demonstrated that ASM cells of asthmatic 
patients promote angiogenesis through elevated secretion of 
the CXC-chemokines ENA-78, GRO-α and IL-8 [99]. 
Endothelial cell sprouting was significantly increased upon 
incubation with culture supernatants of ASM cells of asthma 
patients relative to those of non-asthmatic control subjects 
and that these effects were solely mediated via the CXCR2 
receptor [99; Fig. 3]. Apparently, asthmatic ASM cells 
exhibit an increased potential to synthesize CXCR2 ligands 
and may hence help directing the neovascularization in the 
submucosa of the lungs of asthma patients. Elevated levels 
of ENA-78, GRO-α and IL-8 have indeed been reported to 
be present in the BALF/sputum of asthmatic subjects [99, 
100]. The increased angiogenic potential of ASM cells of 
asthma patients may thus explain the increased vascular 
density in the submucosa observed in the airways of asthma 
patients. These findings supplemented previous studies 
showing that ASM cells are a major source of angiogenic 
factors and that CXCR2 ligands are elevated in the airway 
lining fluids of asthma patients [86, 87]. Studies in several 
model organisms (mice, sheep, and primates) showed that 
HDM allergens increased vascularity of the lungs [101-104]. 
HDM allergens therefore directly contribute to airway wall 
remodeling via a non-immune cell mediated mechanism. 
These data support earlier findings that HDM exerted its 
effect independently of the immune system via resident 
tissue-forming cells [105]. Interestingly, the CXC-
chemokine ENA-78 is selectively degraded by the 
proteolytic activity present in HDM extract [106]. Since 
HDM extract did not have a direct effect on the angiogenic 
potential of ASM cells, the angiogenic effects might be 
mediated by immune or endothelial cells, which may release 
angiogenic mediators upon stimulation with proteases 
present in HDM excrements [105]. Because ENA-78 acts 
primarily on neutrophils, altered ENA-78 levels in the lungs 
may not only affect angiogenic, but also inflammatory 
responses in the airways of asthma patients. Data on 
neutrophil transmigration indeed suggested a diminished 
migration of neutrophils when ENA-78 was incubated with 
HDM extract [106]. Therefore, the presence of proteases 
and/or HDM allergens in the airways may alter the bio-
availability of ENA-78 and modulate both angiogenic and 
immune responses. Similarly, a disturbed release off 
endogenously produced metalloproteinases from activated 
endothelial cells may affect the turnover of vessel-forming 
proteins [107], and influence the angiogenic process. 
Specifically, ADAM33 is thought to play a role in airway 
remodeling because of its high expression in epithelium, 
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myo/fibroblasts, and airway smooth muscle cells and its role 
in promoting angiogenesis and stimulating cell proliferation 
and differentiation [108]. 
 In vivo, the key trigger to induce angiogenesis is hypoxia, 
i.e. the diminished availability of oxygen in organs and 
tissues. Hypoxia is observed in many physiological 
conditions, including embryonic development and 
differentiation or wound healing. In addition, hypoxia occurs 
as the consequences of several pathologies including tumor 
progression, interstitial lung diseases, arteriosclerosis, COPD 
and asthma [109-111]. Hypoxia of the airways can be caused 
by a range of mechanisms, including diminished ventilation 
drive, airway obstruction, intra-alveolar exudates, airway 
wall inflammation, in addition to fibrosis and basement 
membrane thickening [112]. That the ASM cells of asthma 
patients is consuming more oxygen is reflected in the 
increase of mitochondria [113], a phenomenon that may 
further add to locally restricted hypoxia. Moreover, an 
increased ASM mass needs more nutrients and oxygen, 
 
Fig. (3). Neovascularization (spout-outgrowth from human vascular endothelial cells (EC)-spheroids is increased in the presence of super 
natant (Sup Nat) obtained from asthmatic ASM cells (left panel). Images are representative for illustrating sprout outgrowth from EC-
spheroids incubated with supernatants of non-asthmatic and asthmatic ASM cells (as indicated). Lengths of sprouts are indicated as the 
calculated mean (±SD) of the longest 10 sprouts. * p < 0.05. Further details about sprouting and angiogenesis assays can be found in 
references 89 and 106. 
 
Fig. (4). Schematic illustration of the HIF oxygen-sensing pathway. Under normal oxygenation HIF1α is ubiqitinated and degraded in the 
proteasome. Low oxygen concentrations (hypoxia) induce HIF1β, followed by formation of the hetero-dimeric HIF transcription factor, 
which is required for the transcription of angiogenic factors (for details see text). 
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hence more vessels. The increased vascularization in the 
submucosa may contribute to asthma pathology in several 
ways. First, increased vessel leakage may cause tissue edema 
and thereby narrowing of the airways. Second, plasma 
exudation may create and/or aggravate local inflammation 
and remodeling. Third, an increased blood supply provides 
the hyperplastic and hypertrophic ASM cells with the 
required nutritions and oxygen. Reducing the vascularization 
may therefore counteract both airway wall remodeling and 
inflammation. 
 Hypoxia is always associated with the activation of 
proteins of the hypoxia inducible factor (HIF)-family. The 
activation of the HIF-pathway allows the cells to adapt to 
external factors (in this case the low oxygen concentration). 
The major component of hypoxia signaling is the 
transcription factor HIF, which is comprised of two subunits 
(HIF-α and HIF-β). The HIF-1β subunit is constitutively 
expressed and dimerizes with one out of its three potential 
binding partners HIF-1α, HIF-2α or HIF-3α. Under normal 
oxygen conditions (normoxia), the HIF-α proteins have a 
very short half-life and are, by hydroxylation of two proline-
residues in the oxygen-dependent degradation domain, 
constantly targeted for proteasomal degradation [114]. 
Ubiquitinylation of hydroxylated HIFα is mediated by the 
Von Hippel-Lindau protein (VHL) [115]. Under low oxygen 
concentrations hydroxylation is impaired and results in 
increased levels of HIF-α. HIF-α is then translocated to the 
nucleus, dimerizes with the HIF-β subunit and the active 
transcription factor binds to hypoxia response elements in 
the promotor regions of downstream target genes [113]. 
Currently, approximately 100 targets genes of the oxygen-
sensing pathway are known and their corresponding proteins 
are implicated in tissue angiogenesis, erythropoiesis 
ventilation, glycolysis, and autophagy [116]. A simplified 
scheme of the HIF-dependent pathway is presented in Fig. 
(4). 
 Only recently, a role for hypoxia in the pathogenesis of 
asthma has been appreciated. For oxygen supply, ASM cells 
depend on either diffusion though the basement membrane 
or oxygen delivered by microvessels present in the airway 
wall. The airway wall of asthmatics is characterized by 
inflammation and an increased bulk of ASM cells: highly 
active, oxygen consuming tissue. Furthermore, local hypoxic 
conditions may occur due to increased thickness and altered 
composition of the basement membrane, as well as of 
edema, which may affect the rate of oxygen diffusion [117-
119]. The observed increased thickness of the basement 
membrane of asthma patients may induce a locally restricted 
hypoxic environment. In addition, increased oxygen 
consumption, for instance by inflammatory cells and 
growing BSMC may further add to hypoxic conditions in the 
asthmatic lung [117]. Together, these conditions may affect 
the properties and behavior of BSMC, for instance through 
the induction of HIF. In a rat model of asthma, expression of 
the transcription factor HIF was indeed associated with 
airway inflammation, whereas elevated levels of HIF have 
been detected in endobronchial biopsies and in the bronchial 
alveolar lavage fluid of asthmatics [110, 120]. Furthermore, 
increased levels of HIF subunits (HIF-1α and HIF-1β) were 
found in lung tissues and epithelial cells of asthmatic 
patients and correlated with VEGF [120]. Recently, we 
showed that hypoxia significantly reduced the proliferation 
of BSMC of both asthmatic and non-asthmatic subjects, but 
with differential responses [121]. Under moderate hypoxic 
conditions (5% O2), only asthmatic ASM cells significantly 
reduced proliferation, leaving that of non-asthmatic control 
cells unaffected. Stringent hypoxic conditions (1% O2) 
significantly reduced the proliferation of ASM cells from 
both asthmatics and non-asthmatics. The reduced 
proliferation under stringent hypoxic conditions (1% O2) 
was confirmed by lower levels of PCNA- and cyclin E 
proteins in BSMC of asthmatic and non-asthmatic subjects 
[121]. This shows that ASM cells of asthmatics are more 
prone to hypoxic conditions than their non-asthmatic 
counterparts. The reason for this difference is unclear, but it 
might reflect diminished proliferation control responses as 
observed in cultured asthmatic BSMC [51, 53]. In addition, 
we showed that hypoxia enhanced the release of VEGF, and 
the angiogenic cytokines IL-6 and IL-8 in ASM cells, with 
no significant differences between asthmatics and non-
asthmatics [121]. It is unlikely, therefore, that the increased 
vascularization of the submucosa, as it is observed in the 
airway wall of asthma patients, can be ascribed to the release 
of these factors under hypoxic conditions. The finding that 
CXCR2 are important mediators of angiogenesis may 
provide an additional mechanism how angiogenesis in the 
asthmatic airway wall can be induced independently of 
VEGF. 
FUTURE PERSPECTIVE 
 Once thought to be merely an immunological disorder, 
asthma is increasingly recognized as a disease of the airway 
wall with the ASM cells as a major player in inflammatory 
and remodeling responses. Persistent airway wall remodeling 
is now a well-established pathology of the asthmatic lung 
and the major player may well be the ASM cell. Relative to 
their healthy counterparts, ASM cells of asthma patients 
release more cytokines and chemokines, as well as increased 
levels growth and angiogeneic factors (Fig. 5). This suggests 
that the ASM cells of asthma patients are hyper-active (or: 
“primed”) and may thus induce or aggrevate airway wall 
remodeling. This “priming” may also be reflected in the lack 
of efficacy of standard asthma medication in counteracting 
the airway wall remodeling. 
 Usually, asthma is treated with beta-mimetics, with 
glucocorticosteroids (GC), or with a combination of these 
drugs. Beta-mimetics induce the relaxation of ASM cells, 
hence reducing bronchoconstriction, whereas GC are very 
effective at reducing airway inflammation. Despite the 
benificial anti-inflammatory actions of GC, it remains 
controversial whether GC are also able to reduce or reverse 
airway wall remodeling. Recent studies indicate that only 
high doses of inhaled GC can reduce some components of 
airway remodelling, such as the increased airway wall 
vascularity and the basement membrane thickness [122-124]. 
In contrast, GC do not affect ASM cells proliferation and 
associated remodeling [125]. Due to lack of specific targets, 
we currently lack an adequate, non-invasive treatment of the 
“primed” ASM cell. But this may change soon. Recently, we 
performed large-scale profiling analyses of signalling 
pathway activation signatures in ASM cells of asthmatic and 
non-asthmatic subjects [126]. Of the 270 studied signaling 
pathways, we observed that a substantial fraction of them 
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was significantly more active in asthmatic ASM cells, so that 
ASM cells of asthmatic patients can be clearly distinguished 
from those of non-asthmatics. Importantly, the identified 
pathways predominantly represented pathways linked to cell 
proliferation and growth, vascularization, inflammatory 
response and muscle-tissue specific responses, such as 
contractility. This study was the first to provide clear-cut 
evidence for an overall, intrinsic “primed” status of 
asthmatic ASM cells and may reflect the genetically 
predisposition of the disease [126]. 
 The realization that the “primed” ASM cells may be 
pivotal to regulating and controling both inflammation and 
remodeling of the airways may provide an entry to 
completely unexplored fields of asthma treatment. Notably, 
if the airway remodeling – not the inflammation – is the 
primary etiological event leading to asthma as suggested by 
studies in asthmatic children [10-17], then asthma prevention 
might become possible by specifically treating the airway 
smooth muscle cells, averting them to become hyper-active, 
hypertrophic and hyperplastic. Indeed, a new, invasive 
therapy option that specifically addresses the ASM cells has 
already been used in cases of uncontrolled asthma: 
thermoplasty. This treatment involves locally restricted 
heating of the airway wall using radiofrequency energy and 
significantly reduces the mass of ASM [127]. Thermoplastic 
reduction of ASM cells reduced the frequency of asthmatic 
exacerbations [128-133], and in several cases of severe 
asthma, thermoplastic treatment led to a marked reduction of 
asthma symptoms and a stable lung function over a long 
period of time [131]. The efficacy of thermoplasty further 
emphasizes the role of ASM cells in the pathogenesis of 
asthma, which makes the search for non-invasive medication 
and therapeutic strategies that reduce – or even completely 
abrogate – the remodeling processes worthwhile. For 
instance, the increased angiogenic potential of ASM cells of 
asthma patients might be reduced by antagonizing or 
blocking the CXCR2 receptor or its ligands. Studies with 
CXCR2-blockers and ligand-neutralizing agents in the 
context of different diseases, such as rheumatoid arthritis and 
COPD, are ongoing [129, 134]. In vitro, we showed that this 
strategy abrogated the increased sprout outgrowth from EC 
spheroids induced by super natants of asthmatic ASM cells 
[89]. CXCR2 also mediates the recruitment of endothelial 
progenitor cells during allergic airways remodeling [135]. 
Thus, the CXCR2-mediated neovascularization may be 
targeted using extant pharmaceutical compounds and may 
represent a novel strategy to reduce airway remodeling in 
asthma. A more profound discussion on the outcomes of 
recent clinical trials with anti-angiogenic therapies and their 
potentially asthma-resolving properties was recently 
provided by Harkness and coworkers [136]. 
 In conclusion, a fundamental demand exists to develop 
new treatment strategies to tackle the airway wall 
remodeling observed in the lungs of asthma patients. The 
discussed studies demonstrate a pivotal role for a “primed” 
ASM cell in the airway wall remodeling process. Not only 
do they have an increased proliferative capacity, they also 
produce increased levels of growth factors, chemokines and 
 
Fig. (5). Schematic presentation of the proposed central role of the airway smooth muscle (ASM) cell in airway wall remodeling. Due to 
predisposition (intrinsic) and/or environmental (acquired) cues (allergens, hypoxia), ASM cells of patients with asthma are “primed” to 
release abnormal levels of remodeling factors (angiogenic and growthfactors, as well as cytokines and chemokines). 
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cytokines, as wel as angiogenic factors. Targeting the 
“primed” ASM cell to reduce its activity may act as a double 
edged sword. First, reduced numbers of ASM cells will lead 
to diminished airway contraction, hence decreasing the 
bronchi to constrict. Second, reduced numbers of “primed” 
ASM cells will reduce the inflammatory and angiogenic 
mediators in the airway wall and concomitantly reduced 
vascularization. The latter may have profound beneficial 
effects. Blood vessels are the primary portal for immune 
cells to infiltrate tissues and the increased number of blood 
vessels in the airway wall of asthma patients might lead to 
exaggerated inflammation [137]. There is evidence that 
badly controlled asthma results in an increase in 
inflammatory cells, which are entering the airway tissue via 
ancillary blood vessels [138]. Here too, both ASM cells and 
the endothelium might be promising novel targets to reduce 
airway wall remodeling and asthma symptoms. The 
development of (inhaled) anti-angiogenic agents might be an 
interesting new strategy to reduce smooth muscle mass. In 
the fight against cancer, the importance of angiogenesis has 
been recognized and several anti-angiogenic drugs have 
already been positively tested in clinical trials. Developers of 
future asthma therapies may as well look into that direction. 
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